VBI Vaccines (VBIV) vs. Affymax (AFFY) Head to Head Survey
VBI Vaccines (NASDAQ: VBIV) and Affymax (OTCMKTS:AFFY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Institutional & Insider Ownership
21.0% of VBI Vaccines shares are held by institutional investors. 34.1% of VBI Vaccines shares are held by insiders. Comparatively, 1.6% of Affymax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
VBI Vaccines has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500. Comparatively, Affymax has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for VBI Vaccines and Affymax, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
VBI Vaccines currently has a consensus target price of $10.50, suggesting a potential upside of 162.50%. Given VBI Vaccines’ higher probable upside, equities research analysts plainly believe VBI Vaccines is more favorable than Affymax.
This table compares VBI Vaccines and Affymax’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares VBI Vaccines and Affymax’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VBI Vaccines||$550,000.00||464.07||-$23.20 million||N/A||N/A|
Affymax has lower revenue, but higher earnings than VBI Vaccines.
VBI Vaccines beats Affymax on 6 of the 9 factors compared between the two stocks.
About VBI Vaccines
VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Receive News & Ratings for VBI Vaccines Inc. - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. - and related companies with MarketBeat.com's FREE daily email newsletter.